An Evening With Experts: Selecting and Sequencing Therapy in HR+/HER2- Metastatic Breast Cancer

Watch this Webcast and download the slides from a CCO symposium at ASCO 2019 to get up to date on how experts are managing patients with HR-positive, HER2-negative MBC in the context of an evolving treatment paradigm.
Joyce O'Shaughnessy, MD
Program Director
Adam M. Brufsky, MD, PhD
Sara Hurvitz, MD, FACP

Downloadable Slidesets

Download this slideset to review the latest clinical data informing optimal use of CDK4/6 inhibitors in the treatment of HR+/HER2- metastatic breast cancer.

Joyce O'Shaughnessy, MD
Program Director
Released: May 31, 2019

Download this slideset to review the latest clinical data on the evolving role of mTOR, PIK3, and ALK inhibitors in the treatment of HR+/HER2- metastatic breast cancer.

Sara Hurvitz, MD, FACP Released: May 31, 2019

Download this slideset to explore future directions in the treatment of HR+/HER2- metastatic breast cancer, including what to do after progression on a CDK4/6 inhibitor and a review of novel agents in the setting of resistance to standard-of-care therapies.

Adam M. Brufsky, MD, PhD Released: May 31, 2019
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This activity is supported by educational grants from
Lilly
Novartis Pharmaceuticals Corporation

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue